Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Zeev's Turnips - No Politics -- Ignore unavailable to you. Want to Upgrade?

To: Zeev Hed who wrote (55591)	4/24/2002 10:46:52 AM
From: hotlinktuna	Read Replies (1) \| Respond to of 99280

Zeev...you think NFI 24.70 +1.90 w/est. earnings of 3.40 - 3.80 this year up from 2.30 - 2.80 is worth under 30 bucks? Plus I want that .80 dividend next week...<gg> I love this one! I remember suggesting it in the 14 area several months back...what an idiot to sell for a meager gain back then....so it goes! tuna

To: Zeev Hed who wrote (55591)	4/24/2002 10:49:46 AM
From: DennisToo	Read Replies (1) \| Respond to of 99280

Zeev, EXTR...now under 9 you mentioned it yesterday, any thoughts on an entry ? Thanks, D2

To: Zeev Hed who wrote (55591)	4/24/2002 10:57:22 AM
From: Casaubon	Respond to of 99280

don't know if anybody is in this but, Corvas Announces Findings of Preliminary Analyses Of Stroke Trial of UK-279,276 SAN DIEGO, April 23 /PRNewswire-FirstCall/ -- Corvas International, Inc. (Nasdaq: CVAS) announces that preliminary analyses of the multi-center Phase IIb study of UK-279,276 (formerly known as Neutrophil Inhibitory Factor, or rNIF) being conducted by Pfizer Inc (NYSE: PFE) have been completed. Full analysis of the comprehensive and complex dataset from this trial in acute stroke patients is ongoing. Decisions regarding the further development of UK-279,276 will be made upon completion of the full analysis. However, the results from the preliminary analyses of the data relating to the primary endpoint, which represent a small fraction of the predefined statistical analyses, do not support initiation of a Phase III study in stroke. The final results from this trial will be reported following complete data analysis and review, which the company hopes will be available mid-2002. Corvas International, Inc. is a biopharmaceutical company focused on the discovery and development of novel therapeutics that address today's largest medical markets, cardiovascular disease and cancer, based on our expertise in vascular biology and protease modulation. Corvas has a strategic alliance with Pfizer for the development and commercialization of UK-279,276. Corvas expects to initiate a Phase IIb clinical trial in unstable angina patients in the second half of 2002 with our novel anticoagulant rNAPc2. Our cancer pipeline is based on an enzyme family, genomics-driven approach to the discovery of therapeutic products that modulate the activity of serine proteases associated with the growth and progression of solid tumors.